Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma
- 205 Downloads
Hepatitis B virus (HBV) infection is a major risk factor which can lead to development of hepatocellular carcinoma (HCC). Tissue transglutaminase-2 (TG2) has been shown to be critical for cancer progression. However, how TG2 promotes the progression of HBV-related HCC remains unknown. In this study, we aimed to explore the expression and function of TG2 on HBV-related HCC progression. The expression levels of TG2 were examined in a series of HBV-related HCC tissues and a panel of HCC cell lines. The effects of TG2 knockdown on the proliferation and migration of HBV-related cells were determined. TG2 expression was found to be significantly upregulated in HBV-related HCC tissues. TG2 expression was higher in HBV-related HCC cell lines than HBV-unrelated HCC cell lines. Moreover, inhibition of TG2 in HCC cell lines HepG2.2.15 and Hep3B could inhibit cell proliferation, migration, and invasion in vitro. Our results indicated that TG2 could serve as a promising target for treatment of HBV-related HCC patients.
KeywordsHBV-related HCC TG2 Marker Targeted therapy, metastasis
The work was supported by grants from the National Scientific and Technological Major Project of China (No.2013ZX10004904).
Compliance with ethical standards
For the use of these clinical materials for research purposes, prior patient consent and approval from the Institutional Research Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine were obtained.
- 8.Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC, Lai PB, Cai Z, Peng J, Leng X, Poon RT, Luk JM. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol. 2010;17:2518–25.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, Sood AK, Aggarwal BB, Krishnan S, Gelovani JG, Mehta K. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008;14:2476–83.CrossRefGoogle Scholar
- 12.Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L, Ozpolat B. Elongation factor-2 kinase regulates TG2/beta1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med. 2014;18:2235–51.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Sun Y, Mi W, Cai J, Ying W, Liu F, Lu H, Qiao Y, Jia W, Bi X, Lu N, Liu S, Qian X, Zhao X. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 2008;7:3847–59.CrossRefPubMedGoogle Scholar
- 17.K.D. Brown, Transglutaminase 2 and NF-kappaB: an odd couple that shapes breast cancer phenotype. Breast cancer research and treatment. 137, 329–336 (2013)Google Scholar